Tan, Kar-Tong
Kim, Hyunji
Carrot-Zhang, Jian
Zhang, Yuxiang
Kim, Won Jun
Kugener, Guillaume
Wala, Jeremiah A.
Howard, Thomas P.
Chi, Yueh-Yun
Beroukhim, Rameen
Li, Heng
Ha, Gavin
Alper, Seth L.
Perlman, Elizabeth J.
Mullen, Elizabeth A.
Hahn, William C.
Meyerson, Matthew
Hong, Andrew L.
Funding for this research was provided by:
Children's Oncology Group
National Cancer Institute of the National Institutes of Health (U10CA180886, U24CA196173, U10CA180899)
National Cancer Institute of the National Institutes of Health (U10CA098543, U24CA114766, U10CA098413)
St. Baldrick’s Foundation
PhRMA Foundation (Informatics Fellowship)
NIGMS (T32GM007753, T32GM007739)
Team Path to the Cure
National Cancer Institute (U01 CA176058)
American Cancer Society Professorship
American Cancer Society Mentored Research Scholar Grant (MRSG-18-202-01)
Article History
Received: 13 October 2020
Accepted: 25 June 2021
First Online: 14 July 2021
Declarations
:
: Patients consented to IRB-approved COG AREN03B2 and institutional protocols (Dana-Farber Cancer Institute). Patients and/or their guardians provided written assent/consent to participate. Research performed conformed to the principles of the Helsinki Declaration.
: For COG samples, we obtained consent to publish age, race/ethnicity, and gender.
: The authors declare the following competing financial interests: SLA—Quest Diagnostics; WCH—Thermo Fisher, KSQ Therapeutics, Jubliant Therapeutics, RAPPTA Therapeutics, MPM, Solasta Ventures, iTeos, Frontier Medicines, and Tyra Biosciences; and MM—OrigiMed, Bayer, Ono, Janssen, and Novo. The remaining authors declare that they have no competing interests.